Tissue Regenix Group PLC Director/PDMR Shareholding (6628M)

TIDMTRX

RNS Number : 6628M

Tissue Regenix Group PLC

15 September 2023

Tissue Regenix Group plc

("Tissue Regenix", the "Company" or "the Group")

Director/PDMR Shareholding

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that on 15 September 2023, Brian Phillips, Non-Executive Director, bought 6,773 Ordinary Shares in the Group at a price of 54 pence per share for a total consideration of GBP3,657.42.

As a result, Brian Phillips holds 160,000 Ordinary Shares in the Company representing 0.23% of the total issued share capital.

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Sole Broker has changed its name to Cavendish Capital Markets Limited following completion of its own corporate merger.

For more information:

 
 Tissue Regenix Group plc                                www.tissueregenix.com 
 David Cocke, Chief Financial Officer                          via Walbrook PR 
 
 Cavendish Capital Markets Limited (Nominated 
  Adviser and Broker) 
  Emily Watts/Geoff Nash/George Dollemore - 
   Corporate Finance 
 Nigel Birks/Harriet Ward - ECM 
 
 Walbrook PR (Financial PR and IR)                    Tel: [phone] 
 Alice Woodings/Lianne Applegarth                 [e-mail] 
 
 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL(R)) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies(R). This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                     Brian Phillips 
      ---------------------------------------  --------------------------------------- 
       Reason for the notification 
  2 
      -------------------------------------------------------------------------------- 
 a)    Position/status                          Non-Executive Director 
      ---------------------------------------  --------------------------------------- 
 b)    Initial notification                     Initial notification 
        /Amendment 
      ---------------------------------------  --------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------- 
 a)    Name                                     Tissue Regenix Group plc 
      ---------------------------------------  --------------------------------------- 
 b)    LEI                                       213800PNOD5UHQUFJI36 
      ---------------------------------------  --------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------------- 
 a)    Description of the                       Ordinary Shares of 0.1p each 
        financial instrument, 
        type of instrument 
 
       Identification code                      GB00B5SGVL29 
 
 b)    Nature of the transaction                Purchase 
      ---------------------------------------  --------------------------------------- 
 c)    Price(s) and volume(s) 
                                                -----------------  ----------------- 
                                                 Price(s)           Volume(s) 
                                                -----------------  ----------------- 
                                                 0.54               6,773 
                                                -----------------  ----------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                      6,773 
 
  - Price                                  GBP3,657.42 
 
 e)    Date of the transaction                  15 September 2023 
      ---------------------------------------  --------------------------------------- 
 f)    Place of the transaction                 London Stock Exchange, AIM Market 
      ---------------------------------------  --------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUGDCLDBDGXU

(END) Dow Jones Newswires

September 15, 2023 11:30 ET (15:30 GMT)